BELFAST data analytics company Diaceutics has launched its world-first DXRX diagnostic network digital platform, designed to accelerate the development and commercialisation of precision medicine diagnostics.
DXRX brings together stakeholders from across the industry to collaborate to solve real-world testing issues in a secure standardised way for patients.
And already some 38 laboratories and diagnostic companies are onboarded and two pharma companies are piloting the unique platform.
DXRX provides access to pipeline of global diagnostic testing data on one secure platform and enables industry-wide collaboration to address real-world testing issues for the likes of cancer.
The platform also provides users access to a global expert advisory panel of key opinion leaders from the areas of oncology, including lung cancer research and colorectal research; and pathology, including tissue pathology and uropathology.
Sarah Colgan, head of global marketing at Diaceutics, said: “As we see exponential growth in the number of precision medicine therapies coming to market, our pipeline of global diagnostic testing data points to a growing number of hurdles in the testing ecosystem.
“We need to urgently address these with a better model. The opportunity for collaboration to address these testing hurdles for patients can only be addressed by a transformational solution which is global, digital, and scalable, and that is why DXRX has been launched.
“The fact that it can take years for a biomarker test to reach optimal adoption is unacceptable for patients. The platform has been purpose built to accelerate time to peak therapy prescription by reducing that lag time from years to just months.
“We believe DXRX sets a new industry standard for precision medicine which, until today, has been reliant on a business model entirely unfit for purpose, and it’s exciting to see a network of early collaborations across the industry.
“There is a better way to get every patient the treatment they deserve, and we believe DXRX is that way.”
